SalioGen Therapeutics

SalioGen Therapeutics was founded with the mission to revolutionize gene therapy through its innovative Exact DNA Integration Technology (EDIT) platform. This mammal-derived genome engineering technology aims to provide potentially curative, non-viral gene therapies. SalioGen focuses on addressing genetic disorders, with a particular emphasis on diseases that currently lack effective treatments. Their market focus includes conditions such as cystic fibrosis and various genetic vision impairments.

Notable affiliations include strategic collaborations with companies like Nanite to develop lung-targeting nanoparticles for cystic fibrosis treatment. SalioGen has presented significant data at prestigious conferences such as the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Gene & Cell Therapy (ASGCT). These achievements underscore the company's impact on advancing gene therapy technologies and its potential to transform treatment paradigms for genetic disorders.